Lilly Endowment sells $12.9 million in Eli Lilly stock

INDIANAPOLIS—Lilly Endowment Inc., a significant shareholder in Eli Lilly & Co. (NYSE:LLY), disclosed the sale of 14,685 shares of the pharmaceutical company’s common stock, valued at approximately $12.9 million. The transactions occurred on February 20, 2025, with the shares sold at prices ranging from $877.436 to $880.143 each.

Following these transactions, Lilly Endowment holds 96,621,862 shares in Eli Lilly. The sales were executed in multiple transactions, with weighted average prices provided for each batch of shares sold. The endowment remains a major stakeholder in the company, maintaining its position as a ten percent owner. Analysts maintain a bullish outlook on the stock, with a consensus "Buy" rating and price targets ranging from $620 to $1,190. For deeper insights into Eli Lilly’s valuation and growth prospects, access the comprehensive Pro Research Report available on InvestingPro.

In other recent news, Eli Lilly and Company has made significant financial moves by issuing $6 billion in new debt securities across six tranches with maturities ranging from 2028 to 2065. The proceeds, estimated at $6.46 billion after deductions, are intended for general corporate purposes, potentially including refinancing existing debt and funding capital expenditures. Additionally, Eli Lilly announced a $6.5 billion six-part note offering, which has been rated Aa3 by Moody’s (NYSE:MCO) and A+ by S&P, both with a stable outlook. In another development, Moody’s Ratings upgraded Eli Lilly’s issuer rating and senior unsecured notes to Aa3, citing expectations of robust earnings growth driven by the company’s incretin portfolio and promising late-stage pipeline.

Eli Lilly also reported sustained success with its drug Omvoh for Crohn’s disease, demonstrating efficacy over two years in patients. The VIVID-2 study showed that 92.9% of patients in clinical remission after the first year remained so after the second year, marking a significant advancement in treatment options for inflammatory bowel disease. Furthermore, Bernstein research firm reiterated an Outperform rating for Eli Lilly, setting a price target of $1,100. Analyst Courtney Breen noted favorable data for Eli Lilly’s CagriSema drug and interpreted competitor Novo Nordisk (NYSE:NVO)’s delays as advantageous for Eli Lilly’s market position.

These recent developments reflect Eli Lilly’s strategic financial planning and ongoing commitment to expanding its pharmaceutical portfolio.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.